What Is Altered Intercellular Communication

Altered intercellular communication is the progressive degradation of the signaling networks cells use to coordinate growth, repair, immune defense, and metabolic regulation. With aging, these networks shift toward chronic low-grade inflammation, impaired hormonal signaling, and dysfunctional immune surveillance. It is recognized as one of the twelve hallmarks of aging first formally described in the geroscience literature.

Every tissue in the body depends on precise communication between cells. Hormones relay metabolic instructions across organs. Cytokines coordinate immune responses. Extracellular vesicles shuttle molecular cargo between neighboring and distant cells. When these channels degrade, the consequences cascade: wound healing slows, immune responses become misdirected, metabolic regulation falters, and tissues lose their capacity for coordinated self-renewal.

For anyone interested in longevity, this hallmark occupies a unique position because it acts as a multiplier. A single senescent cell may be harmless in isolation, but the inflammatory signals it broadcasts can push surrounding healthy cells toward dysfunction, amplify other hallmarks like genomic instability and stem cell exhaustion, and erode tissue function far beyond the site of origin. The systemic nature of this hallmark means that interventions targeting it could, in principle, slow deterioration across multiple organ systems simultaneously.

Cells communicate through several overlapping channels. Endocrine signaling uses hormones released into the bloodstream to regulate distant targets, including insulin, cortisol, sex hormones, and growth factors. Paracrine signaling relies on molecules that act locally on neighboring cells, such as cytokines, chemokines, and growth factors released by immune cells. Juxtacrine signaling involves direct physical contact between cell surfaces. Extracellular vesicles, including exosomes, carry proteins, lipids, and RNA fragments between cells. All of these channels deteriorate with age.

One of the most studied mechanisms driving this deterioration is the senescence-associated secretory phenotype, or SASP. When cells enter senescence (a state in which they stop dividing but do not die), they begin secreting a cocktail of inflammatory cytokines (IL-6, IL-1 beta, TNF-alpha), matrix metalloproteinases that degrade surrounding tissue architecture, and growth factors that can promote abnormal cell proliferation in neighbors. The SASP transforms senescent cells from passive bystanders into active disruptors of local tissue homeostasis. Because the immune system itself ages (a process called immunosenescence), it becomes less efficient at clearing these senescent cells, allowing their signals to accumulate.

Beyond the SASP, age-related changes in the gut microbiome contribute to altered systemic signaling. A shifting microbial composition increases intestinal permeability, allowing bacterial products like lipopolysaccharide to enter the bloodstream and activate inflammatory pathways. Hormonal axes decline as well: growth hormone and IGF-1 levels fall, sex hormone profiles change, and cortisol regulation becomes less precise. The net result is a signaling environment biased toward inflammation and away from regeneration, a state that compounds every other hallmark of aging.

The concept of altered intercellular communication as an aging hallmark was formalized in the 2013 hallmarks-of-aging framework and expanded in the 2023 update. Much of the foundational research comes from animal models, particularly studies on parabiosis (joining the circulatory systems of young and old mice), which demonstrated that systemic factors in old blood can accelerate aging in young tissues, and vice versa. These experiments pointed to blood-borne signaling molecules as key mediators of age-related decline. Studies on the SASP have identified specific cytokine profiles associated with senescent cell accumulation, and senolytic compounds (drugs that selectively clear senescent cells) have shown improvements in tissue function and reduced inflammatory markers in aged mice.

Human evidence is more limited but growing. Observational studies consistently link elevated inflammatory markers such as IL-6, TNF-alpha, and hsCRP with accelerated biological aging and increased risk of cardiovascular disease, neurodegeneration, and cancer. Clinical trials of senolytics in humans are in early phases, with small studies in conditions like idiopathic pulmonary fibrosis and diabetic kidney disease showing reductions in senescent cell markers and SASP-associated cytokines. However, no large-scale randomized trial has yet demonstrated that directly targeting altered intercellular communication extends human healthspan or lifespan. The field remains active, with ongoing work on plasma exchange, senolytic drug combinations, and microbiome-based interventions.

Aggressive suppression of inflammatory signaling carries its own risks, since acute inflammation is essential for wound healing, infection control, and cancer surveillance. Senolytic therapies, still experimental in humans, could theoretically impair tissue integrity if they remove cells that, despite being senescent, are providing structural support. Hormone replacement addresses one dimension of this hallmark but introduces its own risk profile depending on the specific hormones, doses, and individual context. Over-reliance on single biomarkers like hsCRP can be misleading, as these markers reflect many processes beyond intercellular communication. Any pharmacological approach to this hallmark should be undertaken with clinical guidance and an understanding that long-term safety data in humans remain sparse.